Idogen signs agreement with global contract research partner
Idogen AB (”Idogen”) today announces that the company has signed an agreement with Advinus Therapeutics, a leading global contract research organization, for synthesis of zebularine for future pre-clinical and clinical trials. Zebularine is a key component in Idogen’s tolerogenic vaccine. The agreement means that zebularine will be synthesized according to current regulations for GMP (”Good Manufacturing Practice”). This represents an important step taken by Idogen towards a product for clinical trials.Idogen is starting cooperation to synthesis the company’s drug candidate zebularine in